Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1674
This examiner grants 61% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17310279 | TARGETED DELIVERY OF IFN GAMMA USING ANTIBODY FUSION PROTEINS | Final Rejection | The Regents of the University of California |
| 17183904 | COMPOSITIONS COMPRISING IL6R ANTIBODIES FOR THE TREATMENT OF UVEITIS AND MACULAR EDEMA AND METHODS OF USING SAME | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18364503 | ENGINEERED NATURAL LIGAND-BASED CAR: DIRECTED EVOLUTION OF THE STRESS-RECEPTOR NKP30 | Non-Final OA | THE TRUSTEES OF DARTMOUTH COLLEGE |
| 17596421 | METHODS OF PRODUCING AN ANTI-a4B7 ANTIBODY | Final Rejection | Takeda Pharmaceutical Company Limited |
| 17290128 | PEPTIDES, COMPOSITIONS AND VACCINES FOR TREATMENT OF MICROSATELLITE INSTABLITY HYPERMUTATED TUMORS AND METHODS OF USE THEREOF | Non-Final OA | Icahn School of Medicine at Mount Sinai |
| 17599468 | COMPOSITIONS AND METHODS FOR PREPARING T CELL COMPOSITIONS AND USES THEREOF | Non-Final OA | BIONTECH US INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy